MATTHEW CONYERS: Open Payments
NPI 1992926422 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$675 in 31 payments from 13 companies in 2025. Trend: 2023 $634 · 2024 $337 · 2025 $675
Food & beverage: $675
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $231 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $97 |
| AstraZeneca Pharmaceuticals LP | 4 | $67 |
| Lilly USA, LLC | 2 | $56 |
| Insmed, Inc. | 2 | $48 |
| Amgen Inc. | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk Inc | 1 | $21 |
| Boston Scientific Corporation | 1 | $20 |
Products named: TRELEGY ELLIPTA, AIRSUPRA, KISUNLA, Arikayce, JARDIANCE, OTEZLA, OPSUMIT, VOQUEZNA.
Industry payments across FL — which companies pay providers there.
